Glecaprevir and pibrentasvir and Larotrectinib
Determining the interaction of Glecaprevir and pibrentasvir and Larotrectinib and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4, P-glycoprotein (P-gp), or breast cancer resistance protein (BCRP) may increase the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme. When a single 100 mg dose of larotrectinib was coadministered with itraconazole, a potent CYP450 3A4 inhibitor and P-gp and BCRP inhibitor, larotrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.8- and 4.3-fold, respectively, compared to administration of larotrectinib alone. The interaction has not been studied with other, less potent CYP450 3A4 inhibitors. MANAGEMENT: Caution is advised when larotrectinib is used with CYP450 3A4, P-gp, and/or BCRP inhibitors. Patients should be monitored for adverse effects such as neurotoxicity (delirium, dysarthria, dizziness, gait disturbance, paraesthesia, encephalopathy, memory impairment, tremor) and hepatotoxicity (elevations in liver transaminases), and the larotrectinib dosage adjusted as necessary in accordance with the product labeling. References "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4, P-glycoprotein (P-gp), or breast cancer resistance protein (BCRP) may increase the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme. When a single 100 mg dose of larotrectinib was coadministered with itraconazole, a potent CYP450 3A4 inhibitor and P-gp and BCRP inhibitor, larotrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.8- and 4.3-fold, respectively, compared to administration of larotrectinib alone. The interaction has not been studied with other, less potent CYP450 3A4 inhibitors.
MANAGEMENT: Caution is advised when larotrectinib is used with CYP450 3A4, P-gp, and/or BCRP inhibitors. Patients should be monitored for adverse effects such as neurotoxicity (delirium, dysarthria, dizziness, gait disturbance, paraesthesia, encephalopathy, memory impairment, tremor) and hepatotoxicity (elevations in liver transaminases), and the larotrectinib dosage adjusted as necessary in accordance with the product labeling.
- "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: glecaprevir / pibrentasvir
Brand name: Mavyret
Synonyms: Glecaprevir and Pibrentasvir
Generic Name: larotrectinib
Brand name: Vitrakvi
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Glecaprevir and pibrentasvir-Larotrectinib Capsules
- Glecaprevir and pibrentasvir-Larotrectinib Oral Solution
- Glecaprevir and pibrentasvir-Larotrectinib Sulfate
- Glecaprevir and pibrentasvir-Lartruvo
- Glecaprevir and pibrentasvir-Larynex
- Glecaprevir and pibrentasvir-Laryng-O-Jet
- Larotrectinib-Gleevec
- Larotrectinib-Glenmax PEB DM
- Larotrectinib-Glenmax PEB DM FORTE
- Larotrectinib-Gleolan
- Larotrectinib-Gleostine
- Larotrectinib-Gliadel